However, the FOLFIRINOX regimen has unresolved problems regarding dose modification of chemotherapeutic agents and the use of prophylactic granulocyte colony-stimulating factor (G-CSF) in relation to hematological adverse events (AEs), such as febrile neutropenia (FN) and severe neutropenia (NP). Here, CSF3 is linked to Decreased total neutrophil count.